Centene forecasts 2026 adjusted EPS greater than $5.20 as Medicare turnaround reaches breakeven a year early (NYSE:CNC)

Centene (CNC) reported Q3 2026 adjusted EPS of $0.58, exceeding expectations. The company forecasts 2026 adjusted EPS to exceed $5.20, with its Medicare turnaround reaching breakeven a year early, according to CEO Sarah London.

Original reporting
Published Oct 27, 2026, 6:32 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 27, 2026, 6:34 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefEarnings
Primary signal
$CNC
Bullish
high confidence
Mentioned
$CNC
Relevance
8/10
AlphAI data visualization · based on seekingalpha.com
Decision brief

The 30-second read

$CNCBullishMed
01

Why it matters

The raised EPS guidance is a fresh, material data point for investors.

02

Market read

New guidance may drive short‑term price appreciation for CNC.

03

What to watch

Potential cost pressures from rising medical expenses could offset the earnings boost.

Relevance 8/10Novelty 8/10Timing: today

Background

Centene's earnings call provided the latest quarterly results and forward guidance.

Company-level read

Ticker impact

$CNCBullishHigh confidence
Context

Centene reported Q3 adjusted EPS of $0.58 and raised its 2026 adjusted EPS guidance to above $5.20.

Expected impact

potential upside as market prices in the improved earnings outlook

Evidence & confidence

The new EPS guidance exceeds prior expectations for a large‑cap health insurer, a material catalyst for investors.

Market effects

Positive for the health insurance sector as the outlook improvement may lift peers.

U.S. market may see modest buying pressure in the healthcare segment.

Limited; primarily affects U.S. investors focused on health insurers.

Counterpoint

If the guidance assumes optimistic Medicare reforms, any policy reversal could negate the upside.

Key entities

  • Centene Corporation

    U.S. health insurer providing Medicare Advantage plans.

Related articles

$UNHMed

Medicare, Medicaid Overhaul Targets Fraudulent Billing and Unauthorized Marketplace Enrollments

CMS proposed reforms to combat fraud in Medicare, Medicaid, CHIP, and the Health Insurance Marketplace, aiming to save $90B over 10 years. The rule strengthens oversight, requires self-reporting of overpayments, and increases transparency. Managed care stocks fell, including UNH, HUM, CVS, CLOV, CNC, MOH, ELV, and OSCR. Medicare anti-fraud efforts saved $41.9B in 2025, with a $22.30 return per dollar spent.

$CVSMed

11 Medicare Advantage Insurers Sue CMS Over 2027 Star Ratings and Nearly $4 Billion in Payments

Eleven Medicare Advantage insurers, including CVS Health, Elevance Health, and Centene, sued the CMS over 2027 star ratings, claiming nearly $4 billion in potential losses. They argue CMS used unauthorized measures, citing a recent court ruling in Clover Health's favor. Higher ratings affect bonus payments and rebates. CMS is appealing the Clover decision and has not commented on the new lawsuits.

$UNHHighAI 8/10

Positive Medicaid signals, open enrollment trends: Recapping major payers' Q3 results

UnitedHealth Group reported Q3 profit of $4.1B (up from $2.3B YoY) and revenue of $112.7B. CVS Health earned $2.2B (up from a $4B loss YoY) on $108.4B revenue, announcing a split of its pharmacy business. Cigna and Elevance Health each posted $1.4B profit. Centene reduced losses to $71M (from $6.6B YoY) on $50.6B revenue. Humana saw $162M profit (down from $195M) on $41.15B revenue, with positive Medicare enrollment trends.

$HCAMed

Hospital Stocks Soared as Democrats Took Congress

HCA Healthcare (HCA) rose 10.34% to $510.70 on November 4, 2026, following Democratic gains in the U.S. election. Investors anticipate potential policy changes favoring hospitals and Medicaid insurers. Universal Health Services (UHS) and Tenet Healthcare (THC) also saw significant gains. HCA's stock is now valued at $106.68 billion, but analysts warn of potential downside risks if policy changes do not materialize.

High

Centene Surges 10.5% After Truist Securities Reiterates Buy

Centene Corporation's stock surged 10.5% to $74.56 on Wednesday, with a market cap of $37.3B, after Truist Securities, Wells Fargo, and JP Morgan raised their price targets by an average of 7.4%. Truist maintained a Buy rating, while Wells Fargo and JP Morgan adjusted their targets to $75 with Equal-Weight and Neutral ratings, respectively. The average price target is now $77, indicating potential upside.